Susquehanna International Group’s Briacell Therapeutics BCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCTX
SS
CWP
TWC
HWA
Susquehanna International Group's BCTX Position: Q1 2025 in Review
Susquehanna International Group sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 337 shares — an estimated $28.6K sold.
Susquehanna International Group first reported a position in BCTX in Q1 2023 and held it in 8 quarters. The position peaked at $365K in Q4 2023. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.
- Susquehanna International Group reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
- Susquehanna International Group sold 337 Briacell Therapeutics shares in Q1 2025, an estimated $28.6K.
- Susquehanna International Group first reported a position in Briacell Therapeutics in Q1 2023 and held it in 8 quarters.
- Susquehanna International Group's Briacell Therapeutics position peaked at $365K in Q4 2023.
- 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.